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Pulmonary immunization enhances local humoral and cell-medi-
ated mucosal protection, which are critical for vaccination against
lung-specific pathogens such as influenza or tuberculosis. A variety
of nanoparticle (NP) formulations have been tested preclinically
for pulmonary vaccine development, yet the role of NP surface
charge on downstream immune responses remains poorly un-
derstood. We used the Particle Replication in Non-Wetting Tem-
plates (PRINT) process to synthesize hydrogel NPs that varied only
in surface charge and otherwise maintained constant size, shape,
and antigen loading. Pulmonary immunization with ovalbumin
(OVA)-conjugated cationic NPs led to enhanced systemic and lung
antibody titers compared with anionic NPs. Increased antibody
production correlated with robust germinal center B-cell expan-
sion and increased activated CD4+ T-cell populations in lung drain-
ing lymph nodes. Ex vivo treatment of dendritic cells (DCs) with
OVA-conjugated cationic NPs induced robust antigen-specific T-cell
proliferation with ∼100-fold more potency than soluble OVA
alone. Enhanced T-cell expansion correlated with increased ex-
pression of surface MHCII, T-cell coactivating receptors, and key
cytokines/chemokine expression by DCs treated with cationic NPs,
which were not observed with anionic NPs or soluble OVA. To-
gether, these studies highlight the importance of NP surface
charge when designing pulmonary vaccines, and our findings sup-
port the notion that cationic NP platforms engender potent hu-
moral and mucosal immune responses.
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The lung is a primary site of pathogen entry and is thereforea critical target for mucosal vaccination. Conventionally ad-
ministered vaccines (e.g., s.c. or intramuscular injection) provide
strong humoral protection, but often fail to generate mucosal
immunity, especially in the form of IgA (1). Mucosal vaccines not
only provide local protection, but also confer systemic immunity,
including distal mucosal sites (1–3). Mucosal and systemic anti-
body responses require complex cross-talk between innate and
adaptive immune cells. Antigens are first encountered by pro-
fessional antigen presenting cells (APCs), such as dendritic cells
(DCs), at the site of infection or injury. Activated DCs migrate to
the draining lymph node (dLN), where they present antigenic
peptides on MHCII, which allows for activation of antigen-spe-
cific CD4+ T cells. Activated T cells instruct antigen-specific B
cells to form germinal centers (GC) in the dLN where B cells
expand, undergo affinity maturation, and Ig class switch re-
combination, resulting in production of highly specific antibodies
with specialized functions (4). All three cell types (DCs, CD4+ T
cells, and B cells) are required for GC formation, because T-cell–
deficient mice fail to form GCs and DC depleted mice exhibit
reduced antibody production (5–7).
Nanoparticle (NP) formulations are being engineered to im-
prove subunit vaccine approaches that induce pathogen mimicry
while still maintaining the safety of subunit vaccines (8, 9). In the
lung, NP formulations offer potential solutions to overcome
biological barriers and target APCs (2, 10–13). Cationic NP
formulations have been shown to increase mucosal antibody
production following pulmonary or intranasal administration (14,
15), whereas independent studies using anionic NP approaches
show only minimal improvement in antibody production com-
pared with immunization with soluble protein alone (16, 17). To
date, no direct evaluation of NP surface charge on mucosal im-
mune responses has been performed, likely due to limitations in
NP formulation that prevent such a comparison without dramat-
ically changing NP composition. Our studies used the unique
Particle Replication in Non-Wetting Template (PRINT) process
to exquisitely control all other nanoparticle characteristics and
specifically investigate the role of NP charge on vaccine responses.
Results
Cationic and Anionic NPs Synthesized Using the PRINT Process Can Be
Reproducibly Functionalized with Ovalbumin. To specifically de-
termine the role of surface charge on NP-based vaccines, we
used a water soluble conjugation scheme to functionalize PRINT
NPs that allows reproducible control over both protein loading
and charge (zeta potential). The PRINT-fabricated hydrogel NPs
used in these studies were inherently cationic [referred to as
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(ζ+)NPs], due to amine-functional groups incorporated into the
NP matrix. Anionic NP [referred to as (ζ−)NP] were generated by
converting the amine groups on (ζ+)NP to terminal carboxylate
groups by using succinic anhydride, yielding a net negative
charge. By using the same initial batch for positively and nega-
tively charged NPs, we were able to control for all other NP
characteristics (size, shape, composition) and isolate charge as
the single variable in these studies. A model antigen, ovalbumin
(OVA), was covalently bound through an amide bond to (ζ+)NPs
through the reaction in Fig. 1A. (ζ−)NPs were covalently bound to
OVA in a similar fashion following the succinylation reaction to yield
a negative charge (Fig. 1B). OVAwas covalently conjugated at 100 ±
10 μg of OVA/mg of NP (n ≥ 5) on both cationic and anionic NPs,
with unreacted amine or carboxylic groups maintaining the overall
net charge. NPs remained monodisperse following OVA loading as
measured by dynamic light scattering (DLS) analysis (Table S1) and
scanning EM (Fig. 1C). Hydrodynamic diameters (Zavg) and low
polydispersity index (PDI) were consistent for all four particle for-
mulations with a slight increase in Zavg upon functionalization, likely
due to OVA conjugation (Table S1). Minor variation in the Zavg was
observed overall between cationic and anionic formulations,
amounting to slight differences in hydrogel swelling in the par-
ticular aqueous conditions of the DLS measurements and the
general error associated with assigning a spherical diameter to
a nonspherical NP (Table S1). However, extensive scanning EM
measurements ensure fidelity between both (ζ+)NP-OVA and (ζ−)
NP-OVA in all three dimensions. These results indicate that
an equivalent amount of OVA was conjugated to both cationic
and anionic PRINT NPs and did not induce particle aggregation.
DCs Treated with Particulate OVA Induce Robust OT-II CD4+ T-Cell
Proliferation ex Vivo. To determine how NP charge affects cellu-
lar uptake, antigen processing, and presentation by MHCII, we
treated bone marrow-derived dendritic cells (BMDCs) (gating
and purity in Fig. S1 A and B) with (ζ+)NP-OVA or (ζ−)NP-
OVA and tested their ability to induce antigen-specific T-cell
proliferation by using CFSE-labeled OVA-specific CD4+ T cells
from transgenic OT-II mice (purity in Fig. S1C). BMDCs treated
with soluble OVA induced T-cell proliferation in a dose-
dependent manner with a 10 μg/mL dose, resulting in ∼77% of
antigen-specific T cells undergoing >3 divisions (Fig. 1D, Upper,
full gating in Fig. S1D). Both (ζ−)NP-OVA and (ζ+)NP-OVA
induced similar responses by using 10-fold lower OVA concen-
trations than soluble controls (Fig. 1D, Middle and Lower, re-
spectively). T-cell proliferation in response to (ζ+)NP-OVA–
treated DCs was even stronger at 0.1 μg/mL OVA dose, whereas
the response to (ζ−)NP-OVA–treated DCs declined precipi-
tously and was undetectable with soluble OVA (Fig. 1D). At the
0.01 μg/mL dose, the (ζ+)NP-OVA–treated DC induced ∼28%
of T cells to undergo >3 divisions with undetectable proliferation
in response to (ζ−)NP-OVA and soluble OVA-treated DCs (Fig.
1D). The ability of DCs treated with (ζ+)NP-OVA to induce
robust T-cell proliferation was highly reproducible, because
similar results were observed with multiple batches of indepen-
dently synthesized NP-OVA and cell preparations (Fig. 1E). From
these data, we conclude that DCs treated with (ζ+)NP-OVA in-
duce more robust T-cell proliferation than (ζ−)NP-OVA and
soluble OVA alone.
(ζ+)NP-OVA Up-Regulates BMDC Costimulatory Receptors, Cytokines,
and Chemokines. The ability of BMDCs treated with cationic NPs
to induce strong OTII T-cell proliferation with ∼100-fold lower
concentrations of soluble OVA could be explained by multiple
mechanisms. One explanation is that cationic NPs bind more
readily to the BMDC surface, resulting in increased antigen
uptake and presentation compared with anionic NP or soluble
OVA. We tested this possibility by incorporating a pH-sensitive
dye (pHrodo) during NP fabrication that fluoresces upon in-
ternalization in the endosome. The largest observed difference in
NP uptake occurred at 24 h with 20% fewer pHrodo+ cells in
(ζ−)NP-OVA–treated BMDC cultures compared with (ζ+)NP-
OVA treatment (Fig. S2). By 72 h, ≥94% of DCs were pHrodo+
regardless of NP charge (Fig. S2), suggesting that internalization
at longer time points is not grossly different between (ζ+)NP-OVA
and (ζ−)NP-OVA.
We also hypothesized that (ζ+)NP-OVA–treated DCs induce
stronger T-cell proliferation due to increased MHCII and CD80/
CD86 expression on the DC surface, which would allow for
stronger T-cell receptor engagement and more robust T-cell
activation. Flow cytometric analysis indicated that surface
MHCII, CD80, and CD86 were up-regulated at 72 h after
(ζ+)NP-OVA treatment, which were similar to the expression
Fig. 1. CD4+ OT-II T-cell proliferation in response
to BMDCs treated with ovalbumin functionalized
PRINT particles. (A) Model antigen OVA was co-
valently linked to cationic (ζ+) monodisperse PRINT
80 × 80 × 320 nm particles by using EDC/s-NHS car-
bodiimide chemistry yielding (ζ+)NP-OVA. (B) Amine
groups in (ζ+)NP were converted to carboxylic
groups by using succinic anhydride (i) to yield an-
ionic (ζ−)NP that were covalently linked to OVA by
using the same chemistry as in A. (C) Representative
scanning EM micrograph of functionalized NPs. (D)
Representative CFSE dilution plots of OVA-specific
CD4+VB5.1+ OT-II T-cell division after 72 h coculture
with BMDC treated with equivalent does of OVA
protein. Soluble OVA (Upper), (ζ−) NP-OVA (Middle),
and (ζ+) NP-OVA (Lower). Number represents fre-
quency of OVA-specific CD4+ T cells that underwent
>3 divisions. N.D., not done. (E) Combined data from
three experiments described in A by using indepen-
dently synthesized NP-OVA batches. **P < 0.001 two-
way ANOVA with Sidak’s multiple comparisons test.
Data graphed as mean ± SEM.





















levels observed on LPS-treated DCs after 24 h (Fig. 2A). In
contrast, (ζ−)NP-OVA only induced a modest increase in MHCII
and coreceptor expression compared with untreated controls
(Fig. 2A). Maximal levels of MHCII and coreceptor expression
induced by (ζ+)NP-OVA depended on direct OVA conjugation
to the NP surface, because blank (ζ+)NP alone, or (ζ+)NP ad-
ministered with soluble OVA [(ζ+)NP + sol. OVA], were unable
to induce strong surface expression of these molecules (Fig. 2A).
The increase in coreceptor expression was not due to general up-
regulation of cell surface molecules, because CD11b expression
remained constant among all treatment groups (Fig. 2A). Simi-
lar results were observed at the mRNA level by using quantita-
tive RT-PCR (qRT-PCR) for CD80 and CD86 at 24 and 48 h
after NP treatment (Fig. S3 and Fig. 2B, respectively); however,
the mRNA levels of H2-Aa (MHCII encoding) remained un-
changed, suggesting that up-regulation of surface MHCII occurs
posttranscriptionally.
We further tested whether BMDC cytokine profiles changed
following NP treatment and whether NP charge was a contrib-
uting factor. We found significant increases in IL-6 and IL-12
mRNA expression and protein secretion by DCs treated with
(ζ+)NP-OVA compared with (ζ−)NP-OVA treatment and untreated
controls (Fig. S4 A and B). Increases in key cytokines/chemo-
kines, including Il1b, Il18, Cxcl10, l10, and Ifnb, were detected
after DC treatment with (ζ+)NP-OVA, compared with untreated
or (ζ−)NP-OVA–treated DCs (Fig. S4A). Significant increases in
Il18 and Cxcl10 were observed in DCs treated with (ζ−)NP-OVA
compared with untreated controls; however, at a lower level than
(ζ+)NP-OVA (Fig. S4A). Although Il1b mRNA expression was
elevated in (ζ+)NP-OVA–treated DCs compared with untreated
controls (Fig. S4A), we failed to detect IL-1β protein in the su-
pernatant, which is consistent with previous findings that this
formulation of NPs does not induce inflammasome activation
(18). We also assessed the mRNA expression of several other
cytokines (Ccl2, Tnf, Tgfb1, Il4) and found that they were either
not expressed or were no different from untreated cells (Fig.
S4A). Similar to T-cell coreceptor expression, the increased cy-
tokine expression/secretion required direct OVA conjugation to
the NP, because blank NPs and blank NPs + soluble OVA did not
induce strong cytokine responses (Fig. S4 A and B). These data
suggest that cationic NPs induce an activated DC phenotype that
requires direct conjugation of protein antigen to the NP surface.
(ζ+)NP-OVA Have in Vivo Adjuvant Effects Following Pulmonary
Immunization. It is well established that effective antibody
responses to protein antigens require helper CD4+ T cells. In the
absence of T-cell help, the processes of affinity maturation (en-
hancement of antibody specificity) and Ig isotype switch (IgM to
other effector isotypes; IgG, IgA, or IgE) are severely hindered
(5). Affinity maturation and isotype switch occur within GCs of
dLNs and are comprised of proliferating B cells that up-regulate
the surface marker GL7. We used a model of orotracheal NP
lung instillation to assess primary and secondary CD4+ T-cell–
dependent immune responses, including GC formation and Ig iso-
type switch by using the immunization schedule described in Fig.
S5A. We tested whether particulate OVA induces GC formation
in the local lung draining medistinal LNs following primary and
secondary lung instillations and found significantly higher in-
duction of CD19+GL7+ GC B cells in (ζ+)NP-OVA–treated mice
compared with (ζ−)NP-OVA or soluble OVA alone (Fig. 3 A and
B, full gating in Fig. S5B). Increased GC B-cell populations in
(ζ+)NP-OVA–treated mice were similar to those treated with sol-
uble CpG/OVA (Fig. 3 A and B) and were confined to the draining
mediastinal LN and not observed in the spleen (Fig. S5C), sug-
gesting that induction of GC B cells was due to localized adjuvant
activity in the lung and not due to systemic increases in GC B-cell
populations in these mice. We also investigated the activation
status of CD4+ T cells in the mediastinal lymph node after the
secondary instillation and found a significant increase in the fre-
quency of antigen-experienced CD4+CD44hiCD62lo T cells in
(ζ+)NP-OVA and soluble OVA/CpG-instilled mice compared with
mice-treated soluble OVA alone (Fig. 3C, gating in Fig. S6A). In
contrast, the antigen-experienced CD4+ T-cell population was not
increased in (ζ−)NP-OVA–treated mice compared with soluble
OVA alone (Fig. 3C) and we found no difference in the CD4+
CD44hiCD62lo T-cell populations in spleen (Fig. S6B), suggesting
that the increase in T effector memory cells is specific to the dLN.
Consistent with increased GC formation and antigen-experi-
enced CD4+ T-cell populations, we readily detected OVA-spe-
cific IgG in the plasma and bronchoalveolar lavage fluid (BALF)
of (ζ+)NP-OVA–treated mice following primary and secondary
immunization, with titers comparable to those treated with sol-
uble OVA/CpG (Fig. 4 A and B). Mice treated with (ζ−)NP-
OVA had very low OVA-specific plasma and BALF IgG anti-
body titers that were not statistically different from mice treated
with soluble OVA alone (Fig. 4 A and B). Three of six mice
treated with (ζ+)NP-OVA had detectable levels of OVA-specific
IgA in BALF following primary immunization, whereas no
antigen-specific IgA was detected in any other group, including
soluble OVA/CpG (Fig. 4C, Left). OVA-specific BALF IgA was
only detectable in (ζ+)NP-OVA and soluble OVA/CpG–treated
mice following secondary immunization (Fig. 4C, Right), in-
dicating that (ζ+)NP-OVA has an adjuvant effect capable of
inducing systemic and mucosal antibody responses similar to the
TLR ligand CpG, with no IgA produced in response to (ζ−)NP-
OVA. To determine whether the adjuvant effect(s) of (ζ+)NP-
OVA work through a common mechanism to CpG, we codelivered
soluble CpG with (ζ+)NP-OVA to test for additive effects on
OVA-specific antibody titers. We observed that codelivery of
soluble CpG with (ζ+)NP-OVA significantly increased levels of
OVA-specific BALF IgG and IgA compared with soluble OVA/
CpG (Fig. 4D), suggesting that (ζ+)NP-OVA and CpG work in
an additive fashion to induce more robust antibody responses,
especially for mucosal IgA (Fig. 4D, Right). We also observed
that codelivery of soluble CpG rescued the ability of (ζ−)NP-
OVA to induce BALF IgG and IgA responses (Fig. 4D), sug-
gesting that anionic NPs can still serve as a platform for anti-
gen delivery, but antibody responses require coupling to TLR
Fig. 2. MHCII and T-cell coreceptor expression by BMDC following NP-OVA
treatment. (A) Flow cytometric analysis of surface MHCII (IA/IE), CD80, CD86,
and CD11b (control) expression on CD11b+CD11c+ gated BMDCs 48 h after NP
treatment. Dashed line indicates average expression level on untreated cells
(UT); number indicates MFI. (B) qRT-PCR for mRNA expression of Cd80 Cd86
and H2-Aa (MHCII) by cells treated for 48 h as in A. Data are normalized to
β-actin (Actb) mRNA and graphed as fold change over UT. Equivalent OVA
dose [1 μg/mL] corresponds to [10 μg/mL] NP dose: LPS treatment for 24 h at 10
ng/mL. *P < 0.05, **P < 0.001; LPS group was excluded from statistical analysis.
Representative of three independent experiments. Each experiment used in-
dependently synthesized NP and NP-OVA batches. Bar represents mean ± SEM.
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agonists. From these data, we conclude that cationic NPs contain
inherent adjuvant activity that can further synergize with TLR-
stimulating adjuvants, such as CpG, when delivered to the lung.
The in Vivo Adjuvant Effect(s) of (ζ+)NP-OVA Are Independent of
Endotoxin Contamination. Certain sources of purified OVA con-
tain endotoxin contaminants that can confound the results of
immunization studies. The OVA used thus far in this manuscript
is grade V from Sigma, which has the highest protein purity, but
has also been found in the past (and reported here; Fig. S7), to
contain detectable amounts of endotoxin (19). To test whether
the adjuvant effect(s) we observe in vivo are independent of
OVA-associated endotoxin, we repeated the in vivo immuniza-
tion studies by using NPs conjugated to vaccine grade endotoxin-
free (ef) OVA (Ovalbumin EndoFit; Invivogen, endotoxin levels
in Fig. S7). We found that (ζ+)NP-efOVA still induced OVA-
specific IgG responses in plasma and BALF following primary
immunization, whereas (ζ−)NP-efOVA and soluble efOVA
failed to induce any detectable antigen-specific Ig (Fig. 5A).
Following secondary immunization, the antigen-specific IgG in
plasma and BALF increased in (ζ+)NP-efOVA–treated animals,
but remained undetectable with (ζ−)NP-efOVA and soluble
efOVA treatment, despite the boost dose (Fig. 5B). Additionally,
OVA-specific IgA was exclusively detected in BALF of (ζ+)NP-
efOVA–boosted mice and could not be induced even when
soluble efOVA was codelivered with the FDA approved TLR4
agonist, Monophosphoryl Lipid A (MPLA) (Fig. 5B). Consistent
with increased OVA specific antibody responses, we also observed
expansion of CD19+GL7+ GC B cells in the dLN of (ζ+)NP-
efOVA–treated mice compared with (ζ−)NP-efOVA and soluble
efOVA (Fig. S8 A and B). Our studies using efOVA indicate that
cationic NPs exhibit inherent adjuvant properties in the lung that
induce GC B-cell expansion, as well as mucosal and systemic
antibody production that are independent of endotoxin activity.
Discussion
NP design features, such as size, shape, modulus, and surface
chemistry, are well established for long circulating i.v. delivery;
however, these parameters are mainly unverified for other routes of
administration, especially pulmonary delivery. Our studies used
the PRINT fabrication process to isolate surface charge as the
sole variable in NP-based pulmonary vaccines, while maintaining
identical particle composition, size, shape, and antigen loading.
Our results indicate that cationic hydrogel NPs have adjuvant-
like effects, yielding potent mucosal and systemic antibody
responses following pulmonary delivery, whereas anionic NPs
fail to do so. These responses appear T-cell–dependent, because
they correlate with increased GC formation and Ig class switch
recombination, which are known to require T-cell help (20, 21).
Possible Mechanisms for Enhanced Mucosal and Systemic Antibody
Responses by Cationic NPs. The precise mechanism(s) for how
antigen-conjugated cationic NPs induce mucosal and systemic
antibody responses require further investigation. Previous vac-
cine-related studies using cationic liposomes showed increased
antibody responses over soluble controls; however, this response
was solely attributed to enhanced NP binding to the APC surface
and no differences in costimulatory molecule or cytokine ex-
pression were reported (22–24). We observed that cationic NPs
bound more readily to DCs and macrophages in vitro compared
with anionic NPs; however, the degree of NP internalization was
not grossly different between these groups, especially at longer
time points. Building on previous efforts from our laboratory,
which established that pulmonary delivery of PRINT NPs do not
trigger any lung inflammatory responses by cytokine release or
histopathology (18), neither cationic nor anionic NPs triggered
local lung or systemic increases in the inflammatory cytokines
IL-6, TNF-α, or IL-1β compared with PBS controls. Rather, our
finding that T-cell–activating coreceptors and cytokines are in-
duced with cationic NPs, but not with anionic NPs, suggests a clear
role of NP charge in DC maturation and effector function. Similar
studies using positively charged chitosan-based NPs have also
shown enhanced immune responses over whole protein controls
(15, 25, 26), and recent cationic NP studies using the macrophage
cell line RAW 264.7 have also demonstrated up-regulation of
T-cell costimulatory molecules and cytokines (27). Interestingly,
our studies suggest that the positive charge alone is insufficient for
DC maturation, because this process required protein conjugation
to the NP surface. Therefore, the protein antigen in combination
with select NP characteristics (e.g., positive charge) may be re-
quired for microbial mimicry effects that trigger DC maturation.
The expansion of GC B cells and antigen-experienced CD4+
T cells following cationic NP delivery were confined to the lung
dLN, suggesting that these responses use lung resident immune
populations. Previous studies established that similar-sized NP
(∼200 nm) required lung resident DC transport to the dLN for
induction of potent CD4+ T-cell responses (28, 29). Based on
these studies and our data reported here, we hypothesize that
enhanced antibody responses emanate from cationic NP inter-
action with lung resident DCs that then migrate to the dLN to
induce T-cell–dependent GC formation and antibody production.
Treatment of DCs with (ζ+)NP-OVA ex vivo-induced TH1 skew-
ing cytokine production (IL-12, IL-18), but not TH2 skewing
cytokines (IL-4), suggesting that cationic NPs may instruct TH cell
Fig. 3. GC B-cell formation and CD4+ T-cell activation in mediastinal LNs fol-
lowing pulmonary immunization. (A) Representative flow plots for frequency of
CD19+GL7+ GC B cells in the mediastinal LN following 1° and 2° immunization.
(B) Combined data fromA; 1° immunization, (n ≥ 5) per group; 2° immunization,
n ≥ 10 per group. (C) Frequency of antigen-experienced CD4+CD44hiCD62Llo T
cells in mediastinal LN after 2° immunization (n ≥ 10 per group). *P < 0.05, **P <
0.01, ***P < 0.001, n.s., not significant; one-way ANOVA with Tukey’s multiple
comparisons test. Data in A are representative of two independent experiments.
Data in B and C are combined from two independent experiments. Each exper-
iment used independently synthesized NP and NP-OVA batches. NP dose = 100 μg
per instillation (10 μg of OVA); CpG dose = 2.5 μg per instillation. Line represents
mean ± SEM.





















differentiation. Additionally, increased antibody responses in vivo
may result from enhanced activation of specialized T-follicular
helper cells, which have been shown to be critical for robust GC
formation and antibody production (4). More in-depth studies of
how NP charge affects lung DCs and CD4+ T-cell effector pop-
ulations are needed and are underway.
Synergistic Effects of Cationic NPs and TLR Ligands. Vaccine-grade
OVA coupled to cationic NPs was sufficient to induce robust GC
B-cell expansion and OVA-specific antibody production in vivo,
especially IgA, suggesting that cationic charge confers an adjuvant-
like effect that is independent or additive of TLR activity. Cationic
particles have been shown to bind anionic macromolecules, such as
self-DNA, which may result in low levels of TLR-9 signaling (30,
31). However, use of conventional OVA preparations containing
endotoxin, or the exogenous addition of soluble CpG, enhanced
the capacity of cationic NPs to induce mucosal and systemic an-
tibody responses by two- to sixfold, indicating that controlled ad-
dition of TLR ligands to cationic NPs is a viable option for future
pulmonary subunit vaccine development. Perhaps the most sur-
prising finding from our study was that anionic NPs failed to en-
hance GC formation and antibody responses following pulmonary
delivery. Our ex vivo data indicated that DCs treated with (ζ−)NP-
OVA induced stronger OT-II T-cell proliferation compared with
soluble OVA, and we expected to see a similar trend in our in vivo
studies; however, the response to (ζ−)NP-OVA was no different
from soluble OVA alone. The failure of anionic NPs to induce
immune responses was even more apparent when using vaccine
grade OVA, which did not induce any detectable OVA-specific
antibody. We were able to restore antibody responses to (ζ−)NP-
OVA by coadministering soluble CpG, suggesting that the OVA
conjugated to anionic NPs was still intact, but that the negative
charge lacks the adjuvant effect associated with cationic NPs.
NP Charge as a Critical Design Parameter for Pulmonary Therapeutics.
Our study indicates that consideration of NP charge may be of
critical importance when designing pulmonary therapeutics. We
have demonstrated that cationic NP formulations delivered to
the lung enhance both systemic and mucosal antibody responses
while also providing an adjuvant effect, whereas anionic NPs do
not. However, the use of anionic particles could be advantageous
in cases where immune responses are contraindicated. For ex-
ample, anionic charge with particulate drug depots may afford
stealth-like properties allowing for reduced particle clearance
and sustained therapeutic delivery. Studies by other groups show
that anionic NPs delivered to the lung can induce potent cell-
based immunity by activating CD8+ T-cell responses (16, 17).
Together, these studies suggest that the ability to control NP
Fig. 4. OVA-specific antibody titers in plasma and
BALF of mice following pulmonary immunization
with NP-OVA. (A–D) ELISA for OVA-specific IgG and
IgA. (A) Plasma IgG (n ≥ 15), BALF IgG (n ≥ 5) fol-
lowing 1° immunization. (B) Plasma IgG, BALF IgG
(n ≥ 10) following 2° immunization. (C) BALF IgA levels
following 1° (n ≥ 5) and 2° immunization (n ≥10).
(D) BALF IgG and IgA levels following 2° NP-OVA +
soluble CpG (n ≥ 6). *P < 0.05, **P < 0.001; one-way
ANOVA with Tukey’s multiple comparisons test. Plas-
ma data in A are combined from three independent
experiments, BALF data in A are representative of two
independent experiments. BALF data in B are com-
bined from two independent experiments. Data in C
and D are representative of two independent experi-
ments. Samples from combined experiments were an-
alyzed simultaneously by ELISA; each experiment
used independently synthesized NP and NP-OVA
batches. NP dose = 100 μg per instillation (10 μg of
OVA); CpG dose = 2.5 μg per instillation. Line rep-
resents mean ± SEM.
Fig. 5. OVA-specific antibody titers in plasma and
BALF of mice following pulmonary immunization
with endotoxin-free OVA-conjugated NP (NP-efOVA).
ELISA for OVA-specific IgG and IgA. (A) Plasma IgG
(n = 8), BALF IgG (n = 4) levels following 1° immuniza-
tion. (B) Plasma IgG (n = 4), BALF IgG (n = 4), and BALF
IgA (n = 4) levels following 2° immunization. *P < 0.05,
**P < 0.001; 1-way ANOVA with Tukey’s multiple
comparisons test. NP dose = 100 μg per instillation
(10 μg of OVA); MPLA dose = 0.3 μg per instillation.
Line represents mean ± SEM.
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surface charge offers opportunities to tailor the therapeutic ap-
plication based on desired immunological response.
Continuing to investigate and understand how surface charge
and other particle parameters affect cellular interaction/biological
responses will be critical for engineering novel NP therapeutics.
The degree of control and NP scalability afforded by PRINT allows
for intricate vaccine design with the capacity to alter NP dimen-
sions, use cleavable linkers for antigen/adjuvant conjugation, and
aerosol formulation to provide a portable pulmonary route of ad-
ministration (18, 32). Our findings will hopefully contribute to fu-
ture development of pulmonary-based vaccine platforms that are
applicable to a diverse array of pathogens.
Materials and Methods
Particle Fabrication. Amine-containing 80 × 320 nm hydrogel rod-shaped
NPs were fabricated on a continuous roll-to-roll PRINT method as described (33).
Preparticle solutions contained 1% diphenyl(2,4,6-trimethylbenzoyl)phosphine
oxide, 20% (wt/wt) 2-aminoethyl methacrylate hydrochloride, 10% (wt/wt) poly
(ethylene glycol) diacrylate (Mn∼700), 0–1% functional fluorescent dye, and
69–68% (wt/wt) tetra(ethylene glycol) monoacrylate. OVA functionalization
was achieved by using carbodiimide chemistry. Characterization of NPs is de-
scribed in SI Materials andMethods.
OT-II Coculture. Cell preparation and additional analysis are described in
SI Materials and Methods. On day 0, BMDCs were seeded in RPMI 1640 with
glutamine (Gibco) and 10% (vol/vol) FBS in a round-bottom 96-well plate. NPs
or soluble OVAwere added on day 1 based onmass of OVA per well. On day 2,
splenocytes from OT-II mice were harvested and purified. CD4+ OT-II T cells
were labeled by using CellTrace Violet (CFSE analog, referred to in the text as
CFSE) following manufacturer’s protocol (Life Technologies). T cells were
added to NP-treated BMDCs. Cells were harvested 72 h after T-cell addition.
Pulmonary Delivery and Immunizations. All studies were conducted in accor-
dance with National Institutes of Health guidelines for the care and use of
laboratory animals and approved by the Institutional Animal Care and Use
Committee at the University of North Carolina (UNC). All animals were
maintained in pathogen-free facilities at UNC and were between 8 and 15 wk
of age. C57BL/6 mice were obtained from Jackson Laboratories and OT-II
transgenic mice were bred in-house. NP and control formulations were de-
livered to the lungs of anesthetized mice through an orotracheal instillation
in a 50-μL volume. NP doses were 100 μg of NP per instillation, corresponding
to 10 μg of OVA per instillation, which was used as the control soluble OVA
dose; in studies with adjuvant, 2.5 μg of CpG per instillation or 0.3 μg of
MPLA per instillation was also delivered. For single-dose immunization
studies, a dose was give on day 0 and euthanasia performed on day 9. For
prime and boost immunization studies, doses were given on day 0 and 10,
with submandibular bleeds performed on day 9 and euthanasia on day 20.
Characterization of tissue preparation, antibody responses, GC formation,
and T-cell activation is described in SI Materials and Methods.
Statistical Analysis. Statistical analyses were performed with GraphPad Prism
version 6. Analysis of groups was performed as indicated in figures. All data
points were included in the analyses, and no outliers were excluded in cal-
culations of means or statistical significance.
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